The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment

European Journal of Pharmacology

Volumn 810, Issue , 2017, Pages 100-111

  Ayoub, Nehad M ^a   Siddique, Abu Bakar ^b   Ebrahim, Hassan Y ^b   Mohyeldin, Mohamed M ^b   El Sayed, Khalid A ^b  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

( ) Oleocanthal; 17 estradiol; Breast cancer; Estrogen receptor; Luminal B; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; OLEOCANTHAL; OLIVE OIL; PHENOL DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG; ALDEHYDE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LUMINAL B BREAST CANCER; LUMINAL BREAST CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; MOLECULAR DOCKING; PATHOLOGY; PROTEIN CONFORMATION; TUMOR CELL LINE;

ALDEHYDES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR DOCKING SIMULATION; OLIVE OIL; PHENOLS; PROTEIN CONFORMATION; RECEPTORS, ESTROGEN; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020928848     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.06.019     Document Type: Article

References (49)

1. Abuznait, A.H., Qosa, H., Busnena, B.A., El Sayed, K.A., Kaddoumi, A., Olive-oil-derived oleocanthal enhances beta-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies. ACS Chem. Neurosci. 4 (2013), 973–982, 10.1021/cn400024q.
2. Akl, M.R., Ayoub, N.M., Mohyeldin, M.M., Busnena, B.A., Foudah, A.I., Liu, Y.Y., El Sayed, K.A., Olive phenolics as c-Met inhibitors: (-)-oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS One, 9, 2014, e97622, 10.1371/journal.pone.0097622.
3. Brzozowski, A.M., Pike, A.C., Dauter, Z., Hubbard, R.E., Bonn, T., Engstrom, O., Ohman, L., Greene, G.L., Gustafsson, J.A., Carlquist, M., Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997), 753–758, 10.1038/39645.
4. Chou, T.C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006), 621–681, 10.1124/pr.58.3.10.
5. Chou, T.C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70 (2010), 440–446, 10.1158/0008-5472.CAN-09-1947.
6. Daniel, A.R., Gaviglio, A.L., Knutson, T.P., Ostrander, J.H., D'Assoro, A.B., Ravindranathan, P., Peng, Y., Raj, G.V., Yee, D., Lange, C.A., Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34 (2015), 506–515, 10.1038/onc.2013.579.
7. Elnagar, A.Y., Sylvester, P.W., El Sayed, K.A., (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med. 77 (2011), 1013–1019, 10.1055/s-0030-1270724.
8. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386, 10.1002/ijc.29210.
9. Fini, L., Hotchkiss, E., Fogliano, V., Graziani, G., Romano, M., De Vol, E.B., Qin, H., Selgrad, M., Boland, C.R., Ricciardiello, L., Chemopreventive properties of pinoresinol-rich olive oil involve a selective activation of the ATM-p53 cascade in colon cancer cell lines. Carcinogenesis 29 (2008), 139–146, 10.1093/carcin/bgm255.
10. Fogli, S., Arena, C., Carpi, S., Polini, B., Bertini, S., Digiacomo, M., Gado, F., Saba, A., Saccomanni, G., Breschi, M.C., Nieri, P., Manera, C., Macchia, M., Cytotoxic activity of oleocanthal isolated from virgin olive oil on human melanoma cells. Nutr. Cancer 68 (2016), 873–877, 10.1080/01635581.2016.1180407.
11. Friesner, R.A., Murphy, R.B., Repasky, M.P., Frye, L.L., Greenwood, J.R., Halgren, T.A., Sanschagrin, P.C., Mainz, D.T., Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49 (2006), 6177–6196, 10.1021/jm051256o.
12. Holliday, D.L., Speirs, V., Choosing the right cell line for breast cancer research. Breast Cancer Res., 13, 2011, 215, 10.1186/bcr2889.
13. Holowatyj, A.N., Ruterbusch, J.J., Ratnam, M., Gorski, D.H., Cote, M.L., HER2 status and disparities in luminal breast cancers. Cancer Med. 5 (2016), 2109–2116, 10.1002/cam4.757.
14. Ji, Q.S., Mulvihill, M.J., Rosenfeld-Franklin, M., Cooke, A., Feng, L., Mak, G., O'Connor, M., Yao, Y., Pirritt, C., Buck, E., Eyzaguirre, A., Arnold, L.D., Gibson, N.W., Pachter, J.A., A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol. Cancer Ther. 6 (2007), 2158–2167, 10.1158/1535-7163.MCT-07-0070.
15. Jordan, V.C., Tamoxifen treatment for breast cancer: concept to gold standard. Oncology 11 (1997), 7–13.
16. Katzenellenbogen, J.A., Katzenellenbogen, B.S., Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem. Biol. 3 (1996), 529–536.
17. Keiler, A.M., Djiogue, S., Ehrhardt, T., Zierau, O., Skaltsounis, L., Halabalaki, M., Vollmer, G., Oleocanthal modulates estradiol-induced gene expression involving estrogen receptor alpha. Planta Med. 81 (2015), 1263–1269, 10.1055/s-0035-1546194.
18. Keiler, A.M., Zierau, O., Bernhardt, R., Scharnweber, D., Lemonakis, N., Termetzi, A., Skaltsounis, L., Vollmer, G., Halabalaki, M., Impact of a functionalized olive oil extract on the uterus and the bone in a model of postmenopausal osteoporosis. Eur. J. Nutr. 53 (2014), 1073–1081, 10.1007/s00394-013-0609-4.
19. Khanal, P., Oh, W.K., Yun, H.J., Namgoong, G.M., Ahn, S.G., Kwon, S.M., Choi, H.K., Choi, H.S., p-HPEA-EDA, a phenolic compound of virgin olive oil, activates AMP-activated protein kinase to inhibit carcinogenesis. Carcinogenesis 32 (2011), 545–553, 10.1093/carcin/bgr001.
20. Khanfar, M.A., Bardaweel, S.K., Akl, M.R., El Sayed, K.A., Olive oil-derived oleocanthal as potent inhibitor of mammalian target of rapamycin: biological evaluation and molecular modeling studies. Phytother. Res. 29 (2015), 1776–1782, 10.1002/ptr.5434.
21. LeGendre, O., Breslin, P.A., Foster, D.A., (-)-Oleocanthal rapidly and selectively induces cancer cell death via lysosomal membrane permeabilization. Mol. Cell. Oncol., 2, 2015, e1006077, 10.1080/23723556.2015.1006077.
22. Li, Z.H., Hu, P.H., Tu, J.H., Yu, N.S., Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget, 2016, 10.18632/oncotarget.11344.
23. Lonning, P.E., Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Ther. Adv. Med. Oncol. 4 (2012), 127–137, 10.1177/1758834012439338.
24. Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., Evans, R.M., The nuclear receptor superfamily: the second decade. Cell 83 (1995), 835–839.
25. Margarucci, L., Monti, M.C., Cassiano, C., Mozzicafreddo, M., Angeletti, M., Riccio, R., Tosco, A., Casapullo, A., Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor. Chem. Commun. 49 (2013), 5844–5846, 10.1039/c3cc41858h.
26. Menendez, J.A., Vazquez-Martin, A., Colomer, R., Brunet, J., Carrasco-Pancorbo, A., Garcia-Villalba, R., Fernandez-Gutierrez, A., Segura-Carretero, A., Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer, 7, 2007, 80, 10.1186/1471-2407-7-80.
27. Milosevic, J., Klinge, J., Borg, A.L., Foukakis, T., Bergh, J., Tobin, N.P., Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. BMC Cancer, 13, 2013, 473, 10.1186/1471-2407-13-473.
28. Mohyeldin, M.M., Akl, M.R., Ebrahim, H.Y., Dragoi, A.M., Dykes, S., Cardelli, J.A., El Sayed, K.A., The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor. Oncotarget, 2016, 10.18632/oncotarget.8681.
29. Mohyeldin, M.M., Busnena, B.A., Akl, M.R., Dragoi, A.M., Cardelli, J.A., El Sayed, K.A., Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer. Eur. J. Med. Chem. 118 (2016), 299–315, 10.1016/j.ejmech.2016.04.043.
30. Olsson, M.H., Sondergaard, C.R., Rostkowski, M., Jensen, J.H., PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J. Chem. Theory Comput. 7 (2011), 525–537, 10.1021/ct100578z.
31. Pei, T., Meng, Q., Han, J., Li, H.S., Song, R., Sun, B., Pan, S., Liang, D., Liu, L., (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma. Oncotarget, 2016, 10.18632/oncotarget.9782.
32. Perou, C.M., Borresen-Dale, A.L., Systems biology and genomics of breast cancer. Cold Spring Harb. Perspect. Biol., 2011, 3, 10.1101/cshperspect.a003293.
33. Polyak, K., Breast cancer: origins and evolution. J. Clin. Invest. 117 (2007), 3155–3163, 10.1172/JCI33295.
34. Polyak, K., Heterogeneity in breast cancer. J. Clin. Invest. 121 (2011), 3786–3788, 10.1172/JCI60534.
35. Pritchard, K.I., Endocrine therapy: is the first generation of targeted drugs the last?. J. Intern. Med. 274 (2013), 144–152, 10.1111/joim.12065.
36. Riss, T.L., Moravec, R.A., Niles, A.L., Duellman, S., Benink, H.A., Worzella, T.J., Minor, L., 2004. Cell viability assays. In: Sittampalam, G.S., Coussens, N.P., Nelson, H., Arkin, M., Auld, D., Austin, C., Bejcek, B., Glicksman, M., Inglese, J., Iversen, P.W., Li, Z., McGee, J., McManus, O., Minor, L., Napper, A., Peltier, J.M., Riss, T., Trask, O.J., Jr., Weidner, J. (Eds.), Assay Guidance Manual. Bethesda, MD.
37. Scotece, M., Gomez, R., Conde, J., Lopez, V., Gomez-Reino, J.J., Lago, F., Smith, A.B. 3rd, Gualillo, O., Further evidence for the anti-inflammatory activity of oleocanthal: inhibition of MIP-1alpha and IL-6 in J774 macrophages and in ATDC5 chondrocytes. Life Sci. 91 (2012), 1229–1235, 10.1016/j.lfs.2012.09.012.
38. Scotece, M., Gomez, R., Conde, J., Lopez, V., Gomez-Reino, J.J., Lago, F., Smith, A.B. 3rd, Gualillo, O., Oleocanthal inhibits proliferation and MIP-1alpha expression in human multiple myeloma cells. Curr. Med. Chem. 20 (2013), 2467–2475.
39. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2017. CA Cancer J. Clin. 67 (2017), 7–30, 10.3322/caac.21387.
40. Subik, K., Lee, J.F., Baxter, L., Strzepek, T., Costello, D., Crowley, P., Xing, L., Hung, M.C., Bonfiglio, T., Hicks, D.G., Tang, P., The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer 4 (2010), 35–41.
41. Tallarida, R.J., An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 319 (2006), 1–7, 10.1124/jpet.106.104117.
42. Tanenbaum, D.M., Wang, Y., Williams, S.P., Sigler, P.B., Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. USA 95 (1998), 5998–6003.
43. Thakkar, J.P., Mehta, D.G., A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 16 (2011), 276–285, 10.1634/theoncologist.2010-0302.
44. Tomaskovic-Crook, E., Thompson, E.W., Thiery, J.P., Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res., 11, 2009, 213, 10.1186/bcr2416.
45. Tran, B., Bedard, P.L., Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res., 13, 2011, 221, 10.1186/bcr2904.
46. Vougogiannopoulou, K., Lemus, C., Halabalaki, M., Pergola, C., Werz, O., Smith, A.B. 3rd, Michel, S., Skaltsounis, L., Deguin, B., One-step semisynthesis of oleacein and the determination as a 5-lipoxygenase inhibitor. J. Nat. Prod. 77 (2014), 441–445, 10.1021/np401010x.
47. Welsh, A.W., Lannin, D.R., Young, G.S., Sherman, M.E., Figueroa, J.D., Henry, N.L., Ryden, L., Kim, C., Love, R.R., Schiff, R., Rimm, D.L., Cytoplasmic estrogen receptor in breast cancer. Clin. Cancer Res. 18 (2012), 118–126, 10.1158/1078-0432.CCR-11-1236.
48. Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., Ignatiadis, M., Sengstag, T., Schutz, F., Goldstein, D.R., Piccart, M., Delorenzi, M., Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res., 10, 2008, R65, 10.1186/bcr2124.
49. Wu, J., Statistical inference for tumor growth inhibition T/C ratio. J. Biopharm. Stat. 20 (2010), 954–964, 10.1080/10543401003618983.